Taken together with the changes in MAPK, NF-κB, and ICAM-1 molecules, it can be inferred that the beneficial effect of sRAGE on renal fibrosis was partly attributed to its inhibitory effect on these MAPK and subsequent inflammatory pathways. The gene discussed is NFKB1; the disease is renal fibrosis.